Sequel Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sequel Pharmaceuticals, Inc.
Minute Insight: Thermo Fisher Scientific Wins FDA Clearance For Preeclampsia Blood Test
The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.
AstraZeneca Proclaims Promising Long-Acting COVID-19 Antibody
AstraZeneca vaccine chief Mark Esser is excited about the first in vitro data on AZD3152 which show that the antibody neutralizes all known variants, from Wuhan to Omicron XBB.1.5.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Women’s Health Expert Panel Addresses Challenges, Opportunities In Post-Roe Era
After years of underfunding, stigmatization and lack of research, companies working on products and services that address women’s health care are gaining traction. But the sector also faces unique challenges, such as gaining approval for ads on major social media platforms.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.